ofloxacin has been researched along with Pneumonia, Pneumococcal in 51 studies
Ofloxacin: A synthetic fluoroquinolone antibacterial agent that inhibits the supercoiling activity of bacterial DNA GYRASE, halting DNA REPLICATION.
9-fluoro-3-methyl-10-(4-methylpiperazin-1-yl)-7-oxo-2,3-dihydro-7H-[1,4]oxazino[2,3,4-ij]quinoline-6-carboxylic acid : An oxazinoquinoline that is 2,3-dihydro-7H-[1,4]oxazino[2,3,4-ij]quinolin-7-one substituted by methyl, carboxy, fluoro, and 4-methylpiperazin-1-yl groups at positions 3, 6, 9, and 10, respectively.
ofloxacin : A racemate comprising equimolar amounts of levofloxacin and dextrofloxacin. It is a synthetic fluoroquinolone antibacterial agent which inhibits the supercoiling activity of bacterial DNA gyrase, halting DNA replication.
Pneumonia, Pneumococcal: A febrile disease caused by STREPTOCOCCUS PNEUMONIAE.
| Excerpt | Relevance | Reference |
|---|---|---|
| "We made an open, noncomparative evaluation of ofloxacin, 400 mg orally bid for 10 days, in 98 subjects with community-acquired pneumonia or pathogen-confirmed bronchitis." | 5.07 | Oral ofloxacin therapy for lower respiratory tract infection. ( Farber, MO; Gentry, LO; Lipsky, B; Rodriguez-Gomez, G; Tucker, B, 1992) |
| "This study aimed to explore the pharmacokinetic features of levofloxacin (LVFX) in Chinese patients with infections and to confirm oral LVFX 500 mg once daily as an optimal treatment regimen based on pharmacokinetic-pharmacodynamic (PK-PD) analysis." | 2.74 | Population pharmacokinetics of oral levofloxacin 500 mg once-daily dosage in community-acquired lower respiratory tract infections: results of a prospective multicenter study in China. ( Cao, GY; Huang, JA; Liu, YB; Shi, YG; Si, B; Sun, SH; Wu, XJ; Xia, QM; Xiao, ZK; Xu, JF; Zhang, J; Zhang, YY, 2009) |
| "Levofloxacin is a new fluoroquinolone active against S." | 2.69 | [Levofloxacin in the treatment of community-acquired pneumococcal pneumonia]. ( Léophonte, P; Veyssier, P, 1999) |
| "Levofloxacine is a fluoroquinolone presenting good anti-pneumococcal activity, including against strains with reduced sensitivity to penicillin." | 2.42 | [Levofloxacine for the treatment of pneumococcal pneumonia: results of a meta-analysis]. ( Bru, JP; Leophonte, P; Veyssier, P, 2003) |
| "Amoxicillin was prescribed in 108 cases, fluoroquinolone in 24 cases, macrolide in 18 cases." | 1.36 | [Urinary pneumococcal or Legionella antigen detection tests and low-spectrum antibiotic therapy for community-acquired pneumonia]. ( Bernardin, G; Cua, E; de Salvador, F; Dellamonica, J; Hyvernat, H; Landraud, L; Risso, K; Roger, PM; Vassallo, M, 2010) |
| "Levofloxacin treatment was supplemented with piperacillin/tazobactam." | 1.33 | Failure of levofloxacin treatment in community-acquired pneumococcal pneumonia. ( Bettaccini, AA; Brigante, G; Endimiani, A; Grossi, P; Luzzaro, F; Toniolo, AQ, 2005) |
| " A pharmacokinetic computerized device was used to simulate serum and epithelial lining fluid (ELF) concentrations." | 1.33 | A pharmacodynamic approach to antimicrobial activity in serum and epithelial lining fluid against in vivo-selected Streptococcus pneumoniae mutants and association with clinical failure in pneumonia. ( Aguilar, L; Alou, L; Cafini, F; Echeverría, O; Giménez, MJ; Pérez-Trallero, E; Prieto, J; Sevillano, D, 2006) |
| "For levofloxacin-treated mice, 2 of 7 (29%) isolates with a levofloxacin minimum inhibitory concentration (MIC) 4 times that of the infecting parent strain had ParC mutations." | 1.33 | Short-course therapy of gemifloxacin effective against pneumococcal pneumonia in mice. ( Bast, DJ; de Azavedo, JC; Dresser, L; Duncan, CL; Low, DE; Mandell, LA; Walker, SE, 2006) |
| "During the last decade some studies have shown that the area under the curve (AUC)/MIC ratio is the pharmacodynamic index that best predicts the efficacies of quinolones, while other studies suggest that the predictive value of the peak concentration/MIC (peak/MIC) ratio is superior to the AUC/MIC ratio in explaining clinical and microbiological outcomes." | 1.32 | Pharmacodynamics of levofloxacin and ciprofloxacin in a murine pneumonia model: peak concentration/MIC versus area under the curve/MIC ratios. ( Fraschini, F; Mattina, R; Mouton, JW; Scaglione, F, 2003) |
| " The pharmacokinetic profiles also reflected the effectiveness of GFLX." | 1.32 | Pharmacodynamics and bactericidal activity of gatifloxacin in experimental pneumonia caused by penicillin-resistant Streptococcus pneumoniae. ( Fukuda, Y; Hirakata, Y; Kadota, J; Kohno, S; Miyazaki, Y; Murata, I; Tashiro, T; Tomono, K; Tsukamoto, K; Yanagihara, K, 2004) |
| " With the resistant isolates, the MICs for ciprofloxacin, gatifloxacin, grepafloxacin, levofloxacin, and trovafloxacin were above the maximal serum drug concentrations reported for standard dosage regimens." | 1.31 | Fluoroquinolone-resistant Streptococcus pneumoniae associated with levofloxacin therapy. ( Drlica, K; Mariano, N; Rahal, JJ; Rahman, N; Segal-Maurer, S; Urban, C; Zhao, X, 2001) |
| "Levofloxacin treatment failed in a patient who had pneumococcal pneumonia and had received three previous courses of levofloxacin therapy." | 1.31 | Levofloxacin treatment failure in a patient with fluoroquinolone-resistant Streptococcus pneumoniae pneumonia. ( Denys, GA; Kays, MB; Smith, DW; Wack, ME, 2002) |
| "Treatment with ofloxacin and ciprofloxacin at 50 mg/kg 18 h after infection did not significantly increase survival rates compared with those of untreated controls." | 1.28 | Antipneumococcal activity of ciprofloxacin, ofloxacin, and temafloxacin in an experimental mouse pneumonia model at various stages of the disease. ( Azoulay-Dupuis, E; Bedos, JP; Hardy, DJ; Pocidalo, JJ; Swanson, RN; Vallée, E, 1991) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 7 (13.73) | 18.2507 |
| 2000's | 39 (76.47) | 29.6817 |
| 2010's | 5 (9.80) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Sánchez-Cuéllar, S | 1 |
| García-Pérez, FJ | 1 |
| Reina, MT | 1 |
| Ho, PL | 1 |
| Cheng, VC | 1 |
| Chow, KH | 1 |
| Hsieh, YC | 1 |
| Chang, LY | 1 |
| Huang, YC | 1 |
| Lin, HC | 1 |
| Huang, LM | 1 |
| Hsueh, PR | 1 |
| Zhang, J | 1 |
| Xu, JF | 1 |
| Liu, YB | 1 |
| Xiao, ZK | 1 |
| Huang, JA | 1 |
| Si, B | 1 |
| Sun, SH | 1 |
| Xia, QM | 1 |
| Wu, XJ | 1 |
| Cao, GY | 1 |
| Shi, YG | 1 |
| Zhang, YY | 1 |
| Roger, PM | 1 |
| Risso, K | 1 |
| Hyvernat, H | 1 |
| Landraud, L | 1 |
| Vassallo, M | 1 |
| Dellamonica, J | 1 |
| de Salvador, F | 1 |
| Cua, E | 1 |
| Bernardin, G | 1 |
| Naba, MR | 1 |
| Araj, GF | 1 |
| Baban, TA | 1 |
| Tabbarah, ZA | 1 |
| Awar, GN | 1 |
| Kanj, SS | 1 |
| Le Falher, G | 1 |
| Makinson, A | 1 |
| Eden, A | 1 |
| Lesnik, A | 1 |
| Le Moing, V | 1 |
| Reynes, J | 1 |
| Gant, CM | 1 |
| Rosingh, AW | 1 |
| López-Hontangas, JL | 1 |
| van der Heijden, M | 1 |
| González-Morán, F | 1 |
| Bijlsma, JJ | 1 |
| Canton, E | 1 |
| Croisier, D | 2 |
| Chavanet, P | 2 |
| Lequeu, C | 2 |
| Ahanou, A | 1 |
| Nierlich, A | 1 |
| Neuwirth, C | 1 |
| Piroth, L | 2 |
| Duong, M | 1 |
| Buisson, M | 1 |
| Portier, H | 2 |
| Bello, S | 1 |
| Torres, A | 1 |
| Rubinstein, E | 1 |
| García-Olmos, M | 1 |
| Parra, A | 1 |
| García-Calvo, G | 1 |
| Ponte, C | 1 |
| Giménez, MJ | 2 |
| Aguilar, L | 2 |
| Soriano, F | 1 |
| Anderson, KB | 1 |
| Tan, JS | 1 |
| File, TM | 2 |
| DiPersio, JR | 1 |
| Willey, BM | 1 |
| Low, DE | 5 |
| Scaglione, F | 1 |
| Mouton, JW | 1 |
| Mattina, R | 1 |
| Fraschini, F | 1 |
| d'Escrivan, T | 1 |
| Roussel-Delvallez, M | 1 |
| Alfandari, S | 1 |
| Guery, B | 1 |
| Sahm, DF | 1 |
| Thornsberry, C | 1 |
| Jones, ME | 1 |
| Karlowsky, JA | 1 |
| Bru, JP | 1 |
| Leophonte, P | 2 |
| Veyssier, P | 2 |
| Etienne, M | 1 |
| Bergoin, E | 1 |
| Charles, PE | 1 |
| Yanagihara, K | 1 |
| Fukuda, Y | 1 |
| Miyazaki, Y | 1 |
| Tsukamoto, K | 1 |
| Hirakata, Y | 1 |
| Tomono, K | 1 |
| Kadota, J | 1 |
| Tashiro, T | 1 |
| Murata, I | 1 |
| Kohno, S | 1 |
| Bast, DJ | 3 |
| Yue, M | 1 |
| Chen, X | 1 |
| Bell, D | 1 |
| Dresser, L | 2 |
| Saskin, R | 1 |
| Mandell, LA | 2 |
| de Azavedo, JC | 3 |
| Zubkov, MN | 1 |
| Carlavilla, AB | 1 |
| López-Medrano, F | 1 |
| Chaves, F | 1 |
| Villena, V | 1 |
| Echave-Sustaeta, J | 1 |
| Aguado, JM | 1 |
| Jones, RN | 1 |
| Fritsche, TR | 1 |
| Sader, HS | 1 |
| Endimiani, A | 1 |
| Brigante, G | 1 |
| Bettaccini, AA | 1 |
| Luzzaro, F | 1 |
| Grossi, P | 1 |
| Toniolo, AQ | 1 |
| Hayashi, K | 1 |
| Kadowaki, SE | 1 |
| Takei, M | 1 |
| Fukuda, H | 1 |
| Carratalá, J | 1 |
| Martín-Herrero, JE | 1 |
| Mykietiuk, A | 1 |
| García-Rey, C | 1 |
| Alou, L | 1 |
| Sevillano, D | 1 |
| Cafini, F | 1 |
| Echeverría, O | 1 |
| Pérez-Trallero, E | 1 |
| Prieto, J | 1 |
| Duncan, CL | 1 |
| Walker, SE | 1 |
| de Cueto, M | 1 |
| Rodríguez, JM | 1 |
| Soriano, MJ | 1 |
| López-Cerero, L | 1 |
| Venero, J | 1 |
| Pascual, A | 1 |
| Calbo, E | 1 |
| Alsina, M | 1 |
| Rodríguez-Carballeira, M | 1 |
| Lite, J | 1 |
| Garau, J | 1 |
| Klesel, N | 1 |
| Geweniger, KH | 1 |
| Koletzki, P | 1 |
| Isert, D | 1 |
| Limbert, M | 1 |
| Markus, A | 1 |
| Riess, G | 1 |
| Schramm, H | 1 |
| Iyer, P | 1 |
| Reinert, RR | 1 |
| Lütticken, R | 1 |
| Lemperle, M | 1 |
| Bryskier, A | 1 |
| Amsden, GW | 1 |
| Graci, DM | 1 |
| Cabelus, LJ | 1 |
| Hejmanowski, LG | 1 |
| Fogarty, C | 1 |
| Goldschmidt, R | 1 |
| Bush, K | 1 |
| Shah, PM | 1 |
| Fogarty, CM | 1 |
| Greenberg, RN | 1 |
| Dunbar, L | 1 |
| Player, R | 1 |
| Marrie, TJ | 1 |
| Kojak, CM | 1 |
| Morgan, N | 1 |
| Williams, RR | 1 |
| Empey, PE | 1 |
| Jennings, HR | 1 |
| Thornton, AC | 1 |
| Rapp, RP | 1 |
| Evans, ME | 1 |
| Urban, C | 1 |
| Rahman, N | 1 |
| Zhao, X | 2 |
| Mariano, N | 1 |
| Segal-Maurer, S | 1 |
| Drlica, K | 2 |
| Rahal, JJ | 1 |
| Bharani, A | 1 |
| Kumar, H | 1 |
| Tillotson, G | 1 |
| Davidson, R | 1 |
| Cavalcanti, R | 1 |
| Brunton, JL | 1 |
| Kibsey, P | 1 |
| Fleming, C | 1 |
| Kays, MB | 1 |
| Smith, DW | 1 |
| Wack, ME | 1 |
| Denys, GA | 1 |
| Ross, JJ | 1 |
| Worthington, MG | 1 |
| Gorbach, SL | 1 |
| Zhanel, GG | 1 |
| Hoban, DJ | 1 |
| Chan, CK | 1 |
| Gentry, LO | 1 |
| Lipsky, B | 1 |
| Farber, MO | 1 |
| Tucker, B | 1 |
| Rodriguez-Gomez, G | 1 |
| Thys, JP | 1 |
| Jacobs, F | 1 |
| Byl, B | 1 |
| Azoulay-Dupuis, E | 1 |
| Bedos, JP | 1 |
| Vallée, E | 1 |
| Hardy, DJ | 1 |
| Swanson, RN | 1 |
| Pocidalo, JJ | 1 |
7 reviews available for ofloxacin and Pneumonia, Pneumococcal
| Article | Year |
|---|---|
[Levofloxacine for the treatment of pneumococcal pneumonia: results of a meta-analysis].
Topics: Acute Disease; Anti-Bacterial Agents; Anti-Infective Agents; Community-Acquired Infections; Humans; | 2003 |
A new dosing paradigm: high-dose, short-course fluoroquinolone therapy for community-acquired pneumonia.
Topics: Community-Acquired Infections; Fluoroquinolones; Humans; Ofloxacin; Pneumonia, Pneumococcal; Safety; | 2003 |
[Efficacy and safety of levofloxacin in low respiratory tract infection].
Topics: Anti-Bacterial Agents; Central Nervous System Diseases; Clinical Trials as Topic; Dermatitis, Atopic | 2004 |
Clinical experience in the management of community-acquired pneumonia: lessons from the use of fluoroquinolones.
Topics: Adult; Anti-Bacterial Agents; Clinical Trials as Topic; Community-Acquired Infections; Drug Resistan | 2006 |
The use of levofloxacin in the treatment of respiratory tract infection.
Topics: Anti-Infective Agents; Bronchitis; Chronic Disease; Community-Acquired Infections; Haemophilus Infec | 2000 |
Fluoroquinolones as pneumococcal therapy: closing the barn door before the horse escapes.
Topics: Anti-Infective Agents; Ciprofloxacin; Drug Resistance, Bacterial; Drug Resistance, Multiple; Humans; | 2001 |
Role of quinolones in the treatment of bronchopulmonary infections, particularly pneumococcal and community-acquired pneumonia.
Topics: Anti-Infective Agents; Bronchitis; Ciprofloxacin; Drug Therapy, Combination; Enoxacin; Humans; Oflox | 1991 |
7 trials available for ofloxacin and Pneumonia, Pneumococcal
| Article | Year |
|---|---|
Population pharmacokinetics of oral levofloxacin 500 mg once-daily dosage in community-acquired lower respiratory tract infections: results of a prospective multicenter study in China.
Topics: Administration, Oral; Adolescent; Adult; Aged; Anti-Bacterial Agents; Bronchitis, Chronic; China; Co | 2009 |
Systemic expression of cytokine production in patients with severe pneumococcal pneumonia: effects of treatment with a beta-lactam versus a fluoroquinolone.
Topics: Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Ceftriaxone; Cytokines; Female; Humans; Inter | 2008 |
A randomized, crossover design study of the pharmacology of extended-spectrum fluoroquinolones for pneumococcal infections.
Topics: Adult; Anti-Infective Agents; Cross-Over Studies; Female; Fluoroquinolones; Humans; Levofloxacin; Ma | 1999 |
[Levofloxacin in the treatment of community-acquired pneumococcal pneumonia].
Topics: Adult; Aged; Amoxicillin; Anti-Infective Agents; Ceftriaxone; Cefuroxime; Clavulanic Acid; Community | 1999 |
Effectiveness of levofloxacin for adult community-acquired pneumonia caused by macrolide-resistant Streptococcus pneumoniae: integrated results from four open-label, multicenter, phase III clinical trials.
Topics: Anti-Bacterial Agents; Anti-Infective Agents; Community-Acquired Infections; Drug Resistance, Microb | 2001 |
Oral ofloxacin therapy for lower respiratory tract infection.
Topics: Administration, Oral; Adult; Age Factors; Aged; Aged, 80 and over; Bronchitis; Drug Administration S | 1992 |
Role of quinolones in the treatment of bronchopulmonary infections, particularly pneumococcal and community-acquired pneumonia.
Topics: Anti-Infective Agents; Bronchitis; Ciprofloxacin; Drug Therapy, Combination; Enoxacin; Humans; Oflox | 1991 |
38 other studies available for ofloxacin and Pneumonia, Pneumococcal
| Article | Year |
|---|---|
[Streptococcus pneumoniae infection: cause or consequence of pulmonary alveolar proteinosis?].
Topics: Drug Therapy, Combination; Humans; Male; Middle Aged; Ofloxacin; Omeprazole; Pneumonia, Pneumococcal | 2008 |
Decreasing prevalence of levofloxacin-resistant Streptococcus pneumoniae in Hong Kong, 2001 to 2007.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Drug Resistance, Bacterial; Hong | 2009 |
Circulation of international clones of levofloxacin non-susceptible Streptococcus pneumoniae in Taiwan.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Amino Acid Substitution; Anti-Bacterial Agents; Base Seq | 2010 |
[Urinary pneumococcal or Legionella antigen detection tests and low-spectrum antibiotic therapy for community-acquired pneumonia].
Topics: Aged; Aged, 80 and over; Amoxicillin; Anti-Bacterial Agents; Antigens, Bacterial; Cohort Studies; Co | 2010 |
Emergence of fluoroquinolone-resistant Streptococcus pneumoniae in Lebanon: a report of three cases.
Topics: Aged; Anti-Bacterial Agents; Cefepime; Ceftazidime; Cephalosporins; Clarithromycin; Drug Resistance, | 2010 |
[Two cases of pulmonary gangrene in HIV-infected patients: favorable outcome without surgery].
Topics: Acetamides; Adult; Alcoholism; Amoxicillin; Anti-Bacterial Agents; Drug Therapy, Combination; Gangre | 2011 |
Serotype distribution and antimicrobial resistance of invasive pneumococcal disease strains in the Comunidad Valenciana, Spain, during the winter of 2009-2010: low PCV7 coverage and high levofloxacin resistance.
Topics: Anti-Bacterial Agents; Drug Resistance, Multiple, Bacterial; Erythromycin; Humans; Levofloxacin; Ofl | 2012 |
Efficacy and pharmacodynamics of simulated human-like treatment with levofloxacin on experimental pneumonia induced with penicillin-resistant pneumococci with various susceptibilities to fluoroquinolones.
Topics: Animals; Anti-Infective Agents; Area Under Curve; Disease Models, Animal; Genotype; Humans; Levoflox | 2002 |
[Pneumococcus and quinolone resistance].
Topics: Adult; Aged; Anti-Bacterial Agents; Anti-Infective Agents; Aza Compounds; Child, Preschool; Ciproflo | 2003 |
Reply to: Efficacy and pharmacodynamics of simulated human-like treatment with levofloxacin on experimental pneumonia induced with penicillin-resistant pneumococci with various susceptibilities to fluoroquinolones.
Topics: Animals; Anti-Infective Agents; Disease Models, Animal; Levofloxacin; Ofloxacin; Penicillin Resistan | 2003 |
Efficacy and pharmacodynamics of gemifloxacin versus levofloxacin in guinea pig pneumococcal pneumonia induced by strains with decreased ciprofloxacin susceptibility.
Topics: Animals; Anti-Infective Agents; Ciprofloxacin; Colony Count, Microbial; Drug Resistance, Bacterial; | 2003 |
Emergence of levofloxacin-resistant pneumococci in immunocompromised adults after therapy for community-acquired pneumonia.
Topics: Adult; Anti-Infective Agents; Community-Acquired Infections; Drug Resistance, Microbial; Humans; Imm | 2003 |
Pharmacodynamics of levofloxacin and ciprofloxacin in a murine pneumonia model: peak concentration/MIC versus area under the curve/MIC ratios.
Topics: Animals; Anti-Infective Agents; Area Under Curve; Ciprofloxacin; Colony Count, Microbial; Dose-Respo | 2003 |
High level of resistance to levofloxacin of Streptococcus pneumoniae following fluoroquinolone therapy.
Topics: Aged; Cefotaxime; Community-Acquired Infections; Dose-Response Relationship, Drug; Drug Resistance, | 2003 |
Factors influencing fluoroquinolone resistance.
Topics: Anti-Infective Agents; Area Under Curve; Ciprofloxacin; Drug Resistance, Bacterial; Humans; Microbia | 2003 |
Mutant selection window in levofloxacin and moxifloxacin treatments of experimental pneumococcal pneumonia in a rabbit model of human therapy.
Topics: Animals; Anti-Infective Agents; Area Under Curve; Aza Compounds; Colony Count, Microbial; DNA, Bacte | 2004 |
Quinolone resistance among pneumococci: therapeutic and diagnostic implications.
Topics: Drug Resistance, Bacterial; Drug Resistance, Multiple, Bacterial; Fluoroquinolones; Humans; Levoflox | 2004 |
Pharmacodynamics and bactericidal activity of gatifloxacin in experimental pneumonia caused by penicillin-resistant Streptococcus pneumoniae.
Topics: Administration, Oral; Animals; Anti-Bacterial Agents; Anti-Infective Agents; Ciprofloxacin; Drug Eva | 2004 |
Novel murine model of pneumococcal pneumonia: use of temperature as a measure of disease severity to compare the efficacies of moxifloxacin and levofloxacin.
Topics: Animals; Anti-Bacterial Agents; Aza Compounds; Body Temperature; Colony Count, Microbial; Disease Mo | 2004 |
[Failure of levofloxacin therapy in two cases of community-acquired pneumonia caused by fluoroquinolone-resistant Streptococcus pneumoniae and complicated with empyema].
Topics: Aged; Anti-Bacterial Agents; Community-Acquired Infections; Drug Resistance, Bacterial; Fluoroquinol | 2005 |
Therapeutic options among broad-spectrum beta-lactams for infections caused by levofloxacin-nonsusceptible Streptococcus pneumoniae.
Topics: Anti-Bacterial Agents; beta-Lactams; Community-Acquired Infections; DNA, Bacterial; Drug Resistance, | 2005 |
Failure of levofloxacin treatment in community-acquired pneumococcal pneumonia.
Topics: Aged; Anti-Bacterial Agents; Bacterial Proteins; Community-Acquired Infections; DNA Topoisomerases, | 2005 |
Efficacy of quinolones against secondary pneumococcal pneumonia after influenza virus infection in mice.
Topics: Animals; Anti-Infective Agents; Ciprofloxacin; Female; Fluoroquinolones; Gatifloxacin; Lung; Mice; M | 2006 |
A pharmacodynamic approach to antimicrobial activity in serum and epithelial lining fluid against in vivo-selected Streptococcus pneumoniae mutants and association with clinical failure in pneumonia.
Topics: Anti-Bacterial Agents; Aza Compounds; Azithromycin; Community-Acquired Infections; Drug Resistance, | 2006 |
Short-course therapy of gemifloxacin effective against pneumococcal pneumonia in mice.
Topics: Animals; Anti-Bacterial Agents; Area Under Curve; Body Temperature; Colony Count, Microbial; Disease | 2006 |
Fatal levofloxacin failure in treatment of a bacteremic patient infected with Streptococcus pneumoniae with a preexisting parC mutation.
Topics: Aged; Anti-Bacterial Agents; Bacteremia; DNA Gyrase; DNA Topoisomerase IV; Drug Resistance, Bacteria | 2008 |
Chemotherapeutic activity of levofloxacin (HR 355, DR-3355) against systemic and localized infections in laboratory animals.
Topics: Abscess; Animals; Anti-Infective Agents; Bacterial Infections; Ciprofloxacin; Female; Granuloma; Kle | 1995 |
A comparative study of the in-vitro activity of levofloxacin against Streptococcus pneumoniae.
Topics: Anti-Bacterial Agents; Anti-Infective Agents; Humans; Levofloxacin; Microbial Sensitivity Tests; Ofl | 1999 |
From the Food and Drug Administration.
Topics: Anti-HIV Agents; Anti-Infective Agents; Community-Acquired Infections; Drug Interactions; Enzyme Inh | 2000 |
Bacteremic pneumonia due to multidrug-resistant pneumococci in 3 patients treated unsuccessfully with azithromycin and successfully with levofloxacin.
Topics: Adult; Aged; Anti-Bacterial Agents; Anti-Infective Agents; Azithromycin; Bacteremia; Drug Resistance | 2000 |
Levofloxacin failure in a patient with pneumococcal pneumonia.
Topics: Anti-Infective Agents; Humans; Levofloxacin; Male; Middle Aged; Ofloxacin; Penicillins; Pneumonia, P | 2001 |
Fluoroquinolone-resistant Streptococcus pneumoniae associated with levofloxacin therapy.
Topics: Aged; Aged, 80 and over; Amino Acid Substitution; Anti-Infective Agents; DNA Gyrase; DNA Topoisomera | 2001 |
Drug points: Diabetes inspidus induced by ofloxacin.
Topics: Adult; Anti-Infective Agents, Urinary; Clarithromycin; Diabetes Insipidus; Drug Therapy, Combination | 2001 |
Resistance to levofloxacin and failure of treatment of pneumococcal pneumonia.
Topics: Adult; Aged; Aged, 80 and over; Anti-Infective Agents; Drug Resistance, Bacterial; Fatal Outcome; Fe | 2002 |
Levofloxacin treatment failure in a patient with fluoroquinolone-resistant Streptococcus pneumoniae pneumonia.
Topics: Anti-Infective Agents; Colony Count, Microbial; DNA Gyrase; DNA Topoisomerase IV; Drug Resistance; D | 2002 |
Resistance to levofloxacin and failure of treatment of pneumococcal pneumonia.
Topics: Aged; Anti-Infective Agents; Bacteremia; Drug Resistance, Bacterial; Fatal Outcome; Humans; Levoflox | 2002 |
Resistance to levofloxacin and failure of treatment of pneumococcal pneumonia.
Topics: Anti-Infective Agents; Drug Resistance, Bacterial; Humans; Levofloxacin; Ofloxacin; Pneumonia, Pneum | 2002 |
Antipneumococcal activity of ciprofloxacin, ofloxacin, and temafloxacin in an experimental mouse pneumonia model at various stages of the disease.
Topics: Amoxicillin; Animals; Anti-Infective Agents; Ciprofloxacin; Disease Models, Animal; Erythromycin; Fe | 1991 |